Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Phoning It In

Bruce N. Cronstein, MD  |  Issue: January 2011  |  January 17, 2011

For all of these agents, there was a warning that the biologic (fill in your favorite) “… and methotrexate both increase immunosuppressive effects; risk of infection. High likelihood serious or life-threatening interaction. Contraindicated unless benefits outweigh risks and no alternatives available.” Nearly every study on biological agents ever published indicates that the benefits of combining a biologic with methotrexate always outweigh the risks. More importantly, for infliximab, the Food and Drug Administration–approved labeling states, “Remicade, used in combination with methotrexate, can reduce signs and symptoms, help stop further joint damage, and improve physical function in patients with moderately to severely active RA.”

This particular finding raises a number of questions, such as, “Who writes this stuff?” The authorship of these online resources is never clear. Is the information in all of the other databases as bad or worse? Is it possible that the information in these databases regarding the use, dose, toxicity, or drug interactions of all other drugs is of equally dubious veracity? Finally, might this disinformation campaign be deliberate?

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In my more paranoid moments, I have even imagined that there is a conspiracy of drug companies trying to diminish the use of methotrexate in the treatment of rheumatic diseases by terminally irritating rheumatologists who prescribe the bulk of it so that we go directly to more expensive biologic agents as first-line drugs. In my alternative paranoid universe, I also imagine that malpractice lawyers are trying to develop the factual bases for a new round of malpractice suits because rheumatologists don’t get sued often enough.

How do we end the nightmare? I propose that we stop the pain using the power of the cloud by posting ratings of drug and disease databases on the ACR website. If that doesn’t work, we can HAQ into the offending database and change the entry. Failing that, we can even be old fashioned and use the telephone to provide the correct information. This time we will shout instead of whisper.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Cronstein is Paul R. Esserman Professor of Medicine at New York University School of Medicine, in New York City.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsDrug Updates Tagged with:DiagnosisMethotrexateTreatment

Related Articles

    Health Video Games Spark Interest, Try to Gain Traction

    November 16, 2015

    In the late 1990s, Thomas Baranowski, PhD, professor of pediatrics specializing in nutrition at the Baylor College of Medicine, Houston, applied for a grant. For years, he had been interested in finding ways to get children to change their diet and physical activity. He decided to try a video game, and he got the money…

    Dr. Wolfe & the National Data Bank for Rheumatic Diseases (NBD)

    April 1, 2008

    A private database becomes a national resource

    Old Drugs Can Learn New Tricks

    November 1, 2011

    Methotrexate and its mechanism of action

    Board Games Expand Rheumatologist’s Social Network, Keep Players’ Minds Sharp

    May 16, 2017

    On many Saturday evenings, Kaleb Michaud, PhD, saves the world from pandemics, harvests barrels of coffee beans to sell at market or helps King Brandur recover the fabled Runic DragonStones. Dr. Michaud, an associate professor in the division of rheumatology and immunology at the University of Nebraska Medical Center (UNMC) in Omaha and also co-director of…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences